I've been following NTII since March of this year and have posted
on misc.invest.stocks on a number of occassions. I believe NTII has
tremendous potential. Their market cap is rediculously low for a
biotech with drugs in Phase II trials. Most biotechs with drugs
developed up to this point command market caps over $100 million.
NTIIs market cap is only $30 million.
All three of NTII's product candidates address huge markets,
Memantine (AIDS dementia, stroke, brain tumors, neuropathic pain, head
injury), Dynorphin A (morphine sparing in chronic and acute pain,
opiate withdrawal symptoms), and CRF (arthritis, cerebral edema).
If any of them are successful, and the clinical trials are positive
so far, NTII will command a market cap at least triple its currrent
level.
I have written an extensive report on NTII. I will be happy to
send it to anyone who is interested if they send their E-Mail address
to John M. de Castro, Ph.D. at psyjdc@panther.gsu.edu |
